Clinical Trial Update: Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial assessing tolerability, efficacy, and pharmacokinetics of ZSP1601 in non-alcoholic steatohepatitis (NASH) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• ZSP1601 (ZSP1601)

Snippet

Sponsor: Guangdong Raynovent Biotech Co., Ltd | Conditions: Non-Alcoholic Steatohepatitis (NASH) | Phase 1, Phase 2 | Status: COMPLETED